B
ased on the results of pivotal clinical trials showing significant reductions in mortality and morbidity in patients with mild to severe symptoms of heart failure, [1] [2] [3] [4] guidelines recommend mineralocorticoid receptor antagonist (MRA) therapy for patients with reduced left ventricular ejection fraction of ≤35% and New York Heart Association class II to IV heart failure symptoms in the absence of contraindications such as renal insufficiency and hyperkalemia. 5 However, MRAs in heart failure are underutilized. 6 Reasons for this underutilization are unclear although healthcare providers may be concerned about the risks of hyperkalemia and renal insufficiency, particularly for patients recently hospitalized with acute decompensated heart failure. MRA therapy is often discontinued when a patient is hospitalized and may not be restarted on discharge. 7 Furthermore, patients not on an MRA at admission are infrequently started during a hospitalization. 8 In addition, certain patient characteristics may increase the risk of adverse events, including age, diabetes mellitus, hypotension, and chronic kidney disease. 9, 10 Given the risks of adverse events, clinical guidelines include clear recommendations for monitoring renal function and electrolyte levels soon after initiation and throughout the course of MRA therapy. 5 The specific recommendations include monitoring within 2 to 3 days after initiation of therapy, again at 7 days, monthly for at least 3 months, and every 3 months thereafter. Compliance with these guideline recommendations for laboratory monitoring after MRA initiation occur infrequently in routine clinical practice. 11 Using Medicare administrative claims data linked to laboratory data from a large laboratory services vendor in 10 states, we examined how these recommendations are implemented in high-risk patients. Furthermore, given the vulnerable period after discharge from a hospitalization, we evaluated whether the setting of MRA initiation influenced appropriate laboratory monitoring after drug initiation.
Methods

Data Sources
We used the US Centers for Medicare and Medicaid Services Virtual Research Data Center to access 100% of 2011 Medicare claims data and corresponding beneficiary summary data for beneficiaries in 10 eastern states (Alabama, Delaware, Florida, Georgia, Maryland, New Jersey, New York, North Carolina, South Carolina, and Virginia). 12 The inpatient files contain institutional claims for hospitalizations and emergency department visits that resulted in a hospitalization. The outpatient files contain institutional claims for services not associated with a hospitalization, including laboratory testing and emergency department visits. The carrier files contain noninstitutional claims, including office-based and independent laboratory testing. Medicare Part D files contain information about medication prescriptions. The beneficiary summary files include demographic characteristics and information about enrollment, mortality, and comorbid conditions as defined by the Chronic Conditions Data Warehouse. 13 The 10 states selected for the analysis coincide with the geographic coverage of the laboratory results data we obtained from a large national laboratory services vendor. All patients in the analysis had laboratory claims data, and a subset also had laboratory results data. For the subset of patients with laboratory results data, we linked these data to the claims data through Medicare beneficiary identifiers, as described previously.
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Study Population
Using Medicare data, we identified fee-for-service beneficiaries ≥65 years with heart failure who were incident users of an MRA. To allow this identification and to allow for assessment of laboratory testing, we required beneficiaries to be alive and enrolled in feefor-service Medicare and a Part D plan for the entire 2011 calendar year. We identified heart failure as of July 1, 2011, using the Chronic Conditions Data Warehouse midyear indicator. We defined incident use of an MRA by the presence of a claim for an MRA prescription fill between May 1, 2011, and September 30, 2011, and the absence of claims for an MRA between January 1, 2011, and April 30, 2011. For patients whose initial prescription fill occurred within 3 days of being discharged from a hospitalization, we considered these patients to have started the medication during the hospitalization. We identified MRAs in the Medicare Part D events files based on generic drug names for eplerenone and spironolactone. Each beneficiary's index date for the analysis was the date of the initial MRA prescription fill.
From the linked laboratory data, we identified the subset of this population with observed results for serum potassium (Logical Observation Identifiers Names and Codes [LOINC] 2823-3) and serum creatinine (LOINC 2160-0). We stratified this subset based on estimated glomerular filtration rate, using the modification of diet in renal disease study equation to calculate estimated glomerular filtration rate. 15 Chronic kidney disease was defined as estimated glomerular filtration rate of ≤60 mL/min per 1.73 m 2 .
Outcomes
The primary outcomes of interest were laboratory testing of creatinine and potassium during 3 time periods around drug initiation according to setting of drug initiation, based on American College of Cardiology/American Heart Association guidelines. We identified testing by using carrier and outpatient claims for specific tests or laboratory panels that included serum creatinine ( We included laboratory tests in the analysis if they occurred during one of the following periods (Table I in the Data Supplement): (1) The initial testing period included the 120 days before the index date. We defined appropriate testing during this period as any measurement of both creatinine and potassium. (2) The early follow-up testing period included the 10 days after the index date. We defined appropriate testing during this period as ≥2 measurements of both creatinine and potassium, based on guideline recommendations for testing at 2 to 3 days after MRA initiation and again at 7 days. (3) The extended follow-up testing period included days 11 through 90 after MRA initiation. We defined appropriate testing during this period as ≥3 measurements of both creatinine and potassium, based on guideline recommendations for monthly testing in the first 3 months after initiation. We also created a combined indicator of appropriate testing across all 3 time periods.
Medicare claims data do not include claims for inpatient laboratory testing, so we made allowances for patients hospitalized during the periods described above. Each hospitalization that occurred during a period was counted as 1 test for both potassium and creatinine during that testing period. Patients who were considered to have started the medication during the hospitalization were credited with 1 test for both potassium and creatinine in the early follow-up period as well. We performed sensitivity analyses using alternate definitions, including giving no credit for hospitalizations during a testing period, and giving credit for 2 tests during the early initiation period for patients initiated as an inpatient, with similar results.
Covariates
We obtained demographic information, including age, sex, and race, from the Medicare beneficiary summary files and comorbid conditions from the Chronic Conditions Data Warehouse 2011 midyear indicators. Comorbid conditions of interest included acquired hypothyroidism; Alzheimer's disease, dementia, or related condition; anemia; asthma; atrial fibrillation; benign prostatic hyperplasia; cancer (colorectal, endometrial, breast, lung, or prostate); chronic kidney disease; chronic obstructive pulmonary disease; depression; diabetes mellitus; hyperlipidemia; hypertension; ischemic heart disease; osteoporosis; rheumatoid arthritis or osteoarthritis; and stroke or transient ischemic attack. We obtained baseline use of angiotensin-converting
WHAT IS KNOWN
• Heart failure guidelines recommend MRA therapy in patients with heart failure with reduced ejection fraction and specify recommendations for monitoring renal function and electrolytes after initiation of MRA therapy.
• Compliance with guideline recommendations for laboratory monitoring after MRA initiation is poor.
WHAT THE STUDY ADDS
• Laboratory monitoring occurs more frequently in high-risk patients with renal insufficiency.
• Laboratory monitoring occurs more frequently for patients initiated on MRA therapy in the inpatient setting compared with in the outpatient setting.
enzyme inhibitor or angiotensin II receptor blocker, β-blockers, or diuretics from the 2011 Part D Drug Event File. We also included a covariate for setting of drug initiation.
Statistical Analysis
We summarized baseline characteristics of the study population by setting, using means with SDs for continuous variables and frequencies with percentages for categorical variables. We summarized laboratory tests and adverse events observed using frequencies with percentages by setting and renal function. We used a multivariable log-binomial regression model to estimate associations between patient characteristics and receipt of monitoring, overall and within each period, adjusting for the covariates listed above. We used SAS version 9.3 (SAS Institute Inc, Cary, NC) for all analyses. This study was approved by the Institutional Review Board of the Duke University Health System.
Results
Patient Characteristics
The study population included 10 443 Medicare beneficiaries with heart failure and incident MRA therapy, of whom 2056 (19.7%) initiated therapy during a hospitalization (Table 1) . A majority of patients had comorbid conditions, including anemia, diabetes mellitus, hypertension, hyperlipidemia, and ischemic heart disease. Almost half of the patients had chronic kidney disease, and 53.3% were taking an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Of patients with outpatient initiation of MRA therapy, 36% had been hospitalized in the previous 6 months. Patients who initiated MRA therapy as inpatients had higher rates of most comorbid conditions and were more likely to be on an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and diuretic compared with patients who initiated as outpatients.
Appropriate Testing After MRA Initiation
Appropriate testing across all time periods occurred for 25.2% of those who initiated as an inpatient but only 2.8% of those who initiated as an outpatient (Table 2) . Patients with inpatient initiation had higher rates of appropriate early and extended post-initiation testing (48.4% and 40.6%, respectively) compared with outpatient initiation (4.6% and 27.3%, respectively). Pre-initiation laboratory results were used to calculate estimated glomerular filtration rate for the 1256 patients with linked laboratory results data. Rates of laboratory testing in the early post-initiation period were similar for patients with chronic kidney disease and without chronic kidney disease (Table 3) . However, in the extended post-initiation period, patients with chronic kidney disease had higher rates of testing compared with patients without chronic kidney disease.
Compared with outpatients, patients who initiated MRA therapy as inpatients had a higher likelihood of appropriate follow-up testing in the early period (risk ratio [ For the subset of patients with laboratory test results, before MRA initiation, 9.8% of patients had hyperkalemia with serum potassium of >5.0 mEq/L and 5.8% had renal insufficiency with serum creatinine of >2.5 mg/dL for men and >2.0 mg/dL for women (Table IV in the Data Supplement). Overall, in the early post-initiation period, few patients had hyperkalemia with serum potassium of >5.5 mEq/L, but 6.4% had renal insufficiency. In the extended post-initiation period, 6.4% of patients had hyperkalemia and 9.3% had renal insufficiency. In the extended post-initiation period, patients with chronic kidney disease had significantly higher rates of both hyperkalemia (7.5%) and renal insufficiency (13.9%) compared with patients without chronic kidney disease.
Discussion
MRA therapy is an effective therapy in heart failure, but frequent laboratory monitoring is recommended to evaluate for hyperkalemia or worsening renal function. We sought to understand whether certain high-risk features would impact appropriate laboratory monitoring. We found that the majority of patients were not monitored according to guideline recommendations, particularly patients who initiated MRA therapy as outpatients. The low rates of monitoring were driven largely by the lack of testing in the early and extended post-initiation periods when adverse drug events might arise.
The most appropriate timing and setting for MRA initiation have not been established. Inpatient initiation is supported by studies showing that patients prescribed an MRA at hospital discharge had much higher rates of use at 3 and 12 months compared with patients not prescribed an MRA at discharge. 16 However, hospitalization for heart failure may be accompanied by volume depletion, renal insufficiency, and hypotension, which may increase the risk for adverse events and prompt medication discontinuation or prevent medication initiation. 7 Our study shows that those initiated on MRA therapy during a hospitalization had higher rates of monitoring in both the early post-initiation period and the extended post-initiation period, which may reflect the higher risk for adverse events for these patients. The hospitalization and post-hospitalization periods represent times of increased access and close follow-up for patients, which may facilitate timely laboratory monitoring when medication changes are made and patient compliance with laboratory orders are assured. Deferring MRA initiation to the outpatient setting seems to decrease both the chances of MRA initiation and the rates of recommended laboratory monitoring.
Notably, we found that many patients who initiated MRA therapy had hyperkalemia or renal insufficiency, which are contraindications for MRA use. However, previous work shows that although patients with chronic kidney disease are at higher risk of adverse events, but despite these risks, patients treated with an MRA had better outcomes compared with patients not treated with an MRA. 9, 17 In addition, MRA therapy has been shown to decrease proteinuria and delay progression of renal dysfunction in patients with chronic kidney disease. [18] [19] [20] We found that compared with patients without chronic kidney disease, patients with chronic kidney disease had similar rates of monitoring in the early postinitiation period but higher rates of appropriate monitoring in the extended follow-up period only although rates were still low. Given the known benefits and the known risks of MRA therapy in patients with chronic kidney disease, appropriate laboratory monitoring is paramount in this population.
Despite the efficacy of MRA therapy, the risk of hyperkalemia is an important safety concern. Hyperkalemia carries a significant risk of mortality and may limit the effectiveness of therapy. 10, 21 In randomized, placebo-controlled trials, rates of hyperkalemia and acute renal insufficiency were higher among patients who received an MRA than among those who received a placebo although these laboratory abnormalities did not negate the benefit of MRAs. 17, [22] [23] [24] In clinical practice, however, after the publication of results from the RALES trial (Randomized Aldactone Evaluation Study), there was a marked increase in prescriptions of MRAs with concomitant increases in adverse events. 10, 21 However, the adverse event rate declined when the rise in MRA use was accompanied by a rise in laboratory monitoring. 25 Although the importance of laboratory monitoring during MRA therapy is clear, further study is warranted to examine whether patients who receive appropriate laboratory monitoring after MRA initiation achieve greater benefits from MRA use than those who do not. Furthermore, prospective trials are needed to determine whether laboratory monitoring frequency can be adjusted based on risk of adverse events. Quality improvement initiatives focused on improving appropriate laboratory monitoring for all patients, particularly higher risk patients, are needed. These efforts should focus not only on increasing appropriate laboratory test ordering but also on improving patient compliance with laboratory testing and clinician follow-up of results with modification of drug therapy if needed. With dedicated systems and personnel, high levels of compliance with laboratory monitoring of high-risk medications are possible. 26 Collaboration with clinical pharmacists, computerized monitoring of testing, and automated alerts have been shown to improve rates of laboratory monitoring.
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Limitations
Our study has limitations. First, the study population consisted of fee-for-service Medicare beneficiaries from 10 states in the mid-Atlantic and southeast regions of the United States, and the results may not be generalizable to younger populations or feefor-service beneficiaries in other geographic regions. Furthermore, we only had laboratory results for a small subset of the study population, so we were unable to assess whether the location of initiation, lack of testing, or abnormal test results were related to adverse events. Second, there were likely unmeasured confounders, as in all retrospective observational studies. Third, the data only captured if and when laboratory testing occurred but not the providers who ordered the tests or the reasons the tests were ordered. Given that the presence of comorbid conditions increased the likelihood of appropriate testing, it is possible that testing rates were related to specific conditions and not MRA initiation. Recently, hospitalized patients were credited with higher rates of appropriate testing, suggesting that laboratory monitoring may have been ordered as part of routine discharge follow-up care and not specifically related to MRA initiation. Furthermore, it is possible that laboratory testing was ordered by a provider during outpatient visits but not completed by the patient. Fourth, we were unable to assess medication dosing, medication discontinuation, or patient adherence; thus, we are unable to determine whether improper dosing or use occurred and their relationships with outcomes.
Conclusions
Regardless of the setting of MRA initiation, rates of appropriate laboratory monitoring before MRA initiation were high, but rates after initiation were poor though patients who initiated therapy in the hospital were more likely to receive appropriate laboratory monitoring. Patients with renal insufficiency were more likely to receive appropriate laboratory monitoring after MRA initiation in the inpatient and outpatient setting compared with patients with normal renal function. Quality No pre-or post-initiation testing 280 (3.3) … *Appropriate pre-initiation testing defined as at least 1 laboratory claim (or hospitalization) within 120 days before drug initiation.
†Appropriate early follow-up testing defined as 2 laboratory claims (or hospitalization or 1 laboratory claim plus discharge from the hospital within 3 days before initial outpatient drug fill) within 10 days after drug initiation.
‡Appropriate extended follow-up testing defined as 3 laboratory claims (or hospitalizations) within days 11-90 after drug initiation. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; and CI, confidence interval.
*Risk ratios were estimated using multivariable log-binomial models. Testing includes allowances for hospitalizations.
